Topical Pazopanib Blocks VEGF-induced vascular leakage and neovascularization in the mouse retina but is ineffective in the rabbit

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 1, 2013, Pages 503-511

  Iwase, Takeshi ^a   Oveson, Brian C ^a   Hashida, Noriyasu ^a   e Silva, Raquel Lima ^a   Shen, Jikui ^a   Krauss, Achim H ^b   Gale, David C ^b   Adamson, Peter ^c   Campochiaro, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; PAZOPANIB; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN;

ANIMAL TISSUE; ARTICLE; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; FEMALE; FLUORESCENCE MICROSCOPY; FLUOROPHOTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RABBIT; RETINA DISEASE; SUBRETINAL NEOVASCULARIZATION; TANDEM MASS SPECTROMETRY; TRANSGENIC MOUSE; VASCULAR LEAKAGE;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANGIOGENESIS INHIBITORS; ANIMALS; BLOOD-RETINAL BARRIER; CAPILLARY PERMEABILITY; FEMALE; FLUOROPHOTOMETRY; INTRAVITREAL INJECTIONS; KIDNEY; LUNG; MANNITOL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; PYRIMIDINES; RABBITS; RETINAL NEOVASCULARIZATION; SPECIES SPECIFICITY; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84874706961     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10473     Document Type: Article

References (35)

1. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102: 520-526.
2. Klein R, Klein B. Vision disorders in diabetes. In: National Diabetes Data Group, ed. Diabetes in America. Washington, DC: National Institutes of Health; 1995:293-330.
3. The Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 1995;102:647-661.
4. Shimizu K, Kobayashi Y, Muraoka K. Midperipheral fundus involvement in diabetic retinopathy. Ophthalmology. 1981;88: 601-612.
5. Nguyen QD, Shah SM, Van Anden E, Sung JU, Vitale S, Campochiaro PA. Supplemental inspired oxygen improves diabetic macular edema; a pilot study. Invest Ophthalmol Vis Sci. 2003;45:617-624.
6. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LEH. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995;92:905-909.
7. Ozaki H, Seo M-S, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol. 2000;156:679-707.
8. Ozaki H, Hayashi H, Vinores SA, Moromizato Y, Campochiaro PA, Oshima K. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res. 1997;64:505-517.
9. Saishin Y, Saishin Y, Takahashi K, Melia M, Vinores SA, Campochiaro PA. Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003;195:210-219.
10. Campochiaro PA; C99-PKC412-003 Study Group. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci. 2004;45:922-931.
11. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006;142:961-969.
12. Nguyen QD, Shah SM, Heier JS, et al. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology. 2009;116:2175-2181.
13. Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology. 2010;117:2146-2151.
14. The Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibzumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmolgy. 2010;117:1064-1077.
15. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokineticpharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007; 6:2012-2021.
16. Takahashi K, Saishin Y, Saishin Y, King A, Levin R, Campochiaro PA. The multi-targeted kinase inhibitor pazopanib causes suppression and regression of choroidal neovascularization. Arch Ophthalmol. 2009;127:494-499.
17. Yafai Y, Yang XM, Niemeyer M. Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats. Eur J Pharmacol. 2011;666:12-18.
18. Mori K, Duh E, Gehlbach P, et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol. 2001;188:253-263.
19. Derevjanik NL, Vinores SA, Xiao W-H, et al. Quantitative assessment of the integrity of the blood-retinal barrier in mice. Invest Ophthalmol Vis Sci. 2002;43:2462-2467.
20. Okamoto N, Tobe T, Hackett SF, et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol. 1997;151:281-291.
21. Tobe T, Okamoto N, Vinores MA, et al. Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest Ophthalmol Vis Sci. 1998;39:180-188.
22. Vinores SA, Gadegbeku C, Campochiaro PA, Green WR. Immunohistochemical localization of blood-retinal barrier breakdown in human diabetics. Am J Pathol. 1989;134:231-235.
23. Vinores SA, Campochiaro PA, Lee A, McGehee R, Gadegbeku C, Green WR. Localization of blood-retinal barrier breakdown in human pathologic specimens by immunohistochemical staining for albumin. Lab Invest. 1990;62:742-750.
24. Thakur A, Scheinman RL, Rao VR, Kompella UB. Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage. Microvasc Res. 2011;82:346-350.
25. Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000;24:357-370.
26. Ke T-L, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000;24:371-384.
27. Takahashi K, Saishin Y, Saishin Y, et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2003;44:409-415.
28. Yanni SE, Clark ML, Yang R, Bingaman DP, Penn JS. The effects of nepafenac and amfenac on retinal angiogenesis. Brain Res Bull. 2010;81:310-319.
29. Kern TS, Miller CM, Du Y, et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes. 2007;56:373-379.
30. Callanan D, Williams P. Topical nepafenac in the treatment of diabetic macular edema. Clin Ophthalmol. 2008;2:689-692.
31. Palanki MSS, Akiyama H, Campochiaro P, et al. Development of prodrug 4-chloro-3-(5-methly-3{[4-(2-pyrrolidin-1-ylethoxy)-phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration. J Med Chem. 2008;51:1546-1559.
32. Doukas J, Mahesh S, Umeda N, et al. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol. 2008;216:29-37.
33. Scheppke L, Aguilar E, Gariano RF, et al. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J Clin Invest. 2008;118:2337-2346.
34. Kiuchi K, Matsuoka M, Wu JC, et al. Mecamylamine suppresses basal and nicotine-stimulated choroidal neovascularization. Invest Ophthalmol Vis Sci. 2008;49:1705-1711.
35. Campochiaro PA, Shah SM, Hafiz G, et al. Topical mecamylamine for diabetic macular edema. Am J Ophthalmol. 2010; 149:839-851.